Magnetic resonance spectroscopic investigation of mitochondrial fuel metabolism and energetics in cultured human fibroblasts: Effects of pyruvate dehydrogenase complex deficiency and dichloroacetate

Molecular Genetics and Metabolism

Volumn 89, Issue 1-2, 2006, Pages 97-105

  Simpson, Nicholas E ^a   Han, Zongchao ^a   Berendzen, Kristen M ^a   Sweeney, Carol A ^a   Oca Cossio, Jose A ^a   Constantinidis, Ioannis ^a   Stacpoole, Peter W ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Dichloroacetate; Fibroblasts; Mitochondria; NMR spectroscopy; Pyruvate dehydrogenase complex deficiency; Stable isotopes

Indexed keywords

CARBON 13; DICHLOROACETIC ACID; GLUCOSE; NUCLEOSIDE DIPHOSPHATASE; NUCLEOSIDE TRIPHOSPHATE; PYRUVATE CARBOXYLASE; PYRUVATE DEHYDROGENASE COMPLEX;

ARTICLE; CELL LABELING; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY TRANSFER; FEMALE; FIBROBLAST; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MITOCHONDRION; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY; RNA SPLICING;

CELLS, CULTURED; DICHLOROACETATE; ENERGY METABOLISM; FEMALE; FIBROBLASTS; GLUCOSE; HUMANS; INFANT; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MITOCHONDRIA; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY DISEASE;

EID: 33747005066     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.04.015     Document Type: Article

References (37)

1. Stacpoole P.W., Kerr D.S., Barnes C., Bunch S.T., Carney P.R., Fennell E.M., Felitsyn N.M., Gilmore R.L., Greer M., Henderson G.N., Hutson A.D., Neiberger R.E., O'Brien R.G., Perkins L.E., Quisling R.G., Shroads A.L., Shuster J.J., Silverstein J.H., Theriaque D.W., and Valenstein E. A controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 117 (2006) 1519-1531
2. P.W. Stacpoole, L.R. Gilbert, Pyruvate dehydrogenase complex activity, in: R.H. Glew, M.D. Rosenthal (Eds.), Clinical cases in medical biochemistry, Oxford University Press, New York, (2006) in press.
3. Lissens W., De Meirleir L., Seneca S., Liebaers I., Brown G.K., Brown R.M., Ito M., Naito E., Kuroda Y., Kerr D.S., Wexler I.D., Patel M.S., Robinson B.H., and Seyda A. Mutations in the X-linked pyruvate dehydrogenase (E1)α subunit gene (PDHA1) in patients with a pyruvate dehydrogenase complex deficiency. Hum. Mutat. 15 (2000) 209-219
4. Robinson B. Lactic acidemia: disorders of pyruvate carboxylase and pyruvate dehydrogenase. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. eighth ed. (2001), McGraw-Hill, New York 2275-2296
5. Scholte H.R., Van Coster R.N., de Jonge P.C., Poorthuis B.J., Jeneson J.A., Andersen B.S., Gregersen N., de Klerk J.B., and Busch H.F. Myopathy in very-long-chain acyl-CoA dehydrogenase deficiency: clinical and biochemical differences with the fatal cardiac phenotype. Neuromuscul. Disord. 9 (1999) 313-319
6. Brunelle J.K., Bell E.L., Quesada N.M., Vercauteren K., Tiranti V., Zeviani M., Scarpulla R.C., and Chandel N.S. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab. 1 (2005) 409-414
7. Ogilvie I., Kennaway N.G., and Shoubridge E.A. A molecular chaperone for mitochondrial complex I assembly is mutated in a progressive encephalopathy. J. Clin. Invest. 115 (2005) 2784-2792
8. Puchowicz M.A., Varnes M.E., Cohen B.H., Friedman N.R., Kerr D.S., and Hoppel C.L. Oxidative phosphorylation analysis: assessing the integrated functional activity of human skeletal muscle mitochondria-case studies. Mitochondrion 4 (2004) 377-385
9. van den Heuvel L.P., Smeitink J.A., and Rodenburg R.J.T. Biochemical examination of fibroblasts in the diagnosis and research of oxidative phosphorylation (OXPHOS) defects. Mitochondrion 4 (2004) 395-401
10. Gropman A.L. Expanding the diagnostic and research toolbox for inborn errors of metabolism: the role of magnetic resonance spectroscopy. Mol. Genet. Metab. 86 (2005) 2-9
11. 13C-NMR spectroscopy. J. Biol. Chem. 263 (1988) 6964-6971
12. 13C isotope isomers. Am. J. Physiol. 259 (1990) H987-H995
13. 13C isotopomer analysis of complex metabolic conditions: substrate oxidation, multiple pyruvate cycles, and gluconeogenesis. Metab. Eng. 6 (2004) 12-24
14. 0-ATPase and how it binds an α-subunit. J. Mol. Biol. 351 (2005) 824-838
15. Padfield K.E., Astrakas L.G., Zhang O., Gopalan S., Dai G., Mindrinos M.N., Tompkins R.G., Rahme L.C., and Tzika A.A. Burn injury causes mitochondrial dysfunction in skeletal muscle. Proc. Natl. Acad. Sci. USA 102 (2005) 5368-5373
16. Scatena R., Messana I., Martorana G.E., Gozzo M.L., Lippa S., Maccaglia A., Bottoni P., Vincenzoni F., Mocca G., Castagnola M., and Giardina B. Mitochondrial damage and metabolic compensatory mechanisms induced by hyperoxia in the U-937 cell line. J. Biochem. Mol. Biol. 37 (2004) 454-459
17. 3 in rats. J. Inorg. Biochem. (2005)
18. 31P magnetic resonance spectroscopy. Clin. Cancer Res. 11 (2005) 3503-3513
19. Schweinsburg B.C., Taylor M.J., Alhassoon O.M., Gonzalez R., Brown G.G., Ellis R.J., Letendre S., Videen J.S., McCutchan J.A., Patterson T.L., and Grant I. Brain mitochondrial injury in human immunodeciciency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J. Neuroviro. 11 (2005) 356-364
20. Marcinek D.J., Schenkman K.A., Ciesielski W.A., Lee D., and Conley K.E. Reduced mitochondrial coupling in vivo alters cellular energetics in aged mouse skeletal muscle. J. Physiol. (2005)
21. Petersen K.F., Dufour S., Befroy D., Garcia R., and Schulman G.I. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 350 (2004) 664-671
22. Burgess S.C., Hausler N., Merritt M., Jeffrey F.M., Storey C., Milde A., Koshy S., Lindner J., Magnuson M.A., Malloy C.R., and Sherry A.D. Impaired tricarboxylic acid cycle activity in mouse livers lacking cytosolic phosphoenolpyruvate carboxykinase. J. Biol. Chem. 279 (2004) 48941-48949
23. Dinopoulos A., Cecil K.M., Schapiro M.B., Papadimitriou A., Hadjigeorgiou G.M., Wong B., deGrauw T., and Egelhoff J.C. Brain MRI and proton MRS findings in infants and children with respiratory chain defects. Neuropediatrie 35 (2005) 290-301
24. Lodi R., Tonon C., Valentino M.L., Iotti S., Clementi V., Malucelli E., Barboni P., Longanesi L., Schimpf S., Wissinger B., Baruzzi A., Barbiroli B., and Carelli V. Deficit of in vivo mitochondrial ATP production in OPA1-related dominant optic atrophy. Ann. Neurol. 56 (2004) 719-723
25. Schapira A., and Lodi R. Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease. Methods Mol. Biol. 277 (2004) 293-307
26. Valentino M.L., Barboni P., Ghelli A., Bucchi L., Rengo C., Achilli A., Torroni A., Lugaresi A., Lodi R., Barbiroli B., Dotti M., Federico A., Baruzzi A., and Carelli V. The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy. Ann. Neurol. 56 (2004) 631-641
27. Tyagi R.K., Azrad A., Degani H., and Salomon Y. Simultaneous extraction of cellular lipids and water-soluble metabolites: Evaluation by NMR spectroscopy. Magn. Reson. Med. 35 (1996) 194-200
28. 13C-NMR isotopomer analysis of anaplerotic pathways in INS-1 cells. J. Biol. Chem. 279 (2004) 44370-44375
29. 13C NMR isotopomer analysis reveals a connection between pyruvate cycling and glucose-stimulated insulin secretion (GSIS). Proc. Natl. Acad. Sci. USA 99 (2002) 2708-2713
30. Owen IV R.O., Mandel R.J., Ammini C.V., Conlon T.J., Kerr D.S., Stacpoole P.W., and Flotte T.R. Gene therapy for pyruvate dehydrogenase E1α deficiency using recombinant adeno-associated virus 2 (rAAV2) vectors. Mol. Ther. 6 (2002) 394-399
31. Okajima K., Warman M.L., Byrne L.C., and Kerr D.S. Somatic mosaicism in a male with an exon skipping mutation in PDHA1 of the pyruvate dehydrogenase complex results in a milder phenotype. Mol. Genet. Metab. 87 (2006) 162-168
32. Stacpoole P.W. The pharmacology of dichloroacetate. Metabolism 28 (1989) 1124-1144
33. Evans O.B., and Stacpoole P.W. Prolonged hypolactatemia and increased total pyruvate dehydrogenase activity by dichloroacetate. Biochem. Pharmacol. 31 (1982) 1295-1300
34. Matthews P.M., Brown R.M., Otero L.J., Marchington D.R., LeGris M., Howes R., Meadows L.S., Shevell M., Scriver C.R., and Brown G.K. Pyruvate dehydrogenase deficiency. Clinical presentation and molecular genetic characterization of five new patients. Brain 117 (1994) 435-443
35. Morten K.J., Caky M., and Matthews P.M. Stabilization of the pyruvate dehydrogenase E1α subunit by dichloroacetate. Neurology 51 (1998) 1331-1335
36. Stacpoole P.W., Moore G.W., and Kornhauser D.M. Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia. N. Engl. J. Med. 298 (1978) 526-530
37. Stacpoole P.W., Harman E.M., Curry S.H., Baumgartner T.G., and Misbin R.I. Treatment of patients with lactic acidosis with dichloroacetate. N. Engl. J. Med. 309 (1983) 390-396